Search results for "genotype 4"

showing 3 items of 3 documents

Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with…

2017

Summary Background We ran a compassionate use nationwide programme (ABACUS) to provide access to ombitasvir, paritaprevir, and ritonavir, with dasabuvir, plus ribavirin for hepatitis C virus (HCV) genotype 1 infection and ombitasvir, paritaprevir, and ritonavir, plus ribavirin for HCV genotype 4 infection in patients with cirrhosis at high risk of decompensation while approval of these regimens was pending in Italy. Methods In this prospective observational study, we collected data from a compassionate use nationwide programme from March 17, 2014, to May 28, 2015. Patients with HCV genotype 1 infection and cirrhosis at high risk of decompensation were given coformulated ombitasvir (25 mg), …

CyclopropanesCompassionate Use TrialsLiver CirrhosisMalechemistry.chemical_compound0302 clinical medicine2-NaphthylamineHCV direct-acting antiviral mixed cryoglobulinemia RBVAnilides030212 general & internal medicineLongitudinal StudiesProspective StudiesChronicAdult; Aged; Anilides; Antiviral Agents; Carbamates; Compassionate Use Trials; Drug Therapy Combination; Female; Genotype; Hepatitis C Chronic; Humans; Liver Cirrhosis; Longitudinal Studies; Macrocyclic Compounds; Male; Middle Aged; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; UracilSettore MED/12 - GastroenterologiaSulfonamidesDasabuvirHCV DAAGastroenterologyvirus diseasesValineMiddle AgedSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis CTreatment OutcomeGastroenterology; HepatologyCombinationDrug Therapy Combination030211 gastroenterology & hepatologyFemalemedicine.drugAdultmedicine.medical_specialtyMacrocyclic CompoundsProlineGenotypeLactams MacrocyclicAdult; Aged; Anilides; Antiviral Agents; Carbamates; Compassionate Use Trials; Drug Therapy Combination; Female; Genotype; Hepatitis C Chronic; Humans; Liver Cirrhosis; Longitudinal Studies; Macrocyclic Compounds; Male; Middle Aged; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Hepatology; GastroenterologyHepatitis C virus genotype 1 Hepatitis C virus genotype 4 decompensated liver cirrhosis antiviral therapy dasabuvir ombitasvir paritaprevirHepatology; GastroenterologyAntiviral Agents03 medical and health sciencesDrug TherapyInternal medicineRibavirinmedicineHumansDecompensationAdverse effectUracilAgedRitonavirHepatologybusiness.industryRibavirinHepatitis C ChronicVirologyOmbitasvirClinical trialchemistryParitaprevirRitonavirCarbamatesbusiness
researchProduct

Phylodynamic Analysis and Implication of HCV Genotype 4 Variability on Antiviral Drug Response and T-Cell Recognition.

2020

Therapies for HCV care could change the prevalence and the geographic distribution of genotypes due to differences in Sustained Virologic Response (SVR). In this scenario, uncommon genotypes/subtypes, such as genotype 4, could spread from high-risk groups, replacing genotypes eradicated by antiviral drugs. Genotype eradication is also strongly influenced by the CD8+ T cell response. In this study, the genetic variability in HCV genotype 4 strains obtained from a cohort of 67 patients na&iuml

Settore MED/07 - Microbiologia E Microbiologia ClinicaT-Lymphocyteslcsh:QR1-502Bayesian analysisHepacivirusViral Nonstructural Proteinslcsh:MicrobiologyCoalescent theoryphylodynamicGenotypegenetic variabilityPhylogenyBayesian analysimedia_commonSettore MED/12 - Gastroenterologiavirus diseasesMiddle Agedviral epitopeHepatitis CHost-Pathogen InteractionInfectious Diseasesmedicine.anatomical_structureHost-Pathogen InteractionsHCVtMRCADrugAdultGenotypemedicine.drug_classmedia_common.quotation_subjectT cellmacromolecular substancesHuman leukocyte antigenBiologyAntiviral AgentsArticleYoung AdultT cell recognitionVirologyDrug Resistance ViralmedicineHumansGenetic variabilitygenotype 4AgedDAAAntiviral AgentHepaciviruVirologydigestive system diseasesviral epitopesAntiviral drugCD8RASViruses
researchProduct

Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection

2020

Data on the prevalence of resistance-associated substitutions (RASs) and their implications for treatment with direct-acting antivirals (DAAs) are sparse in European patients with HCV genotype 4. This study investigated RASs before and after DAA failure in different genotype 4 subtypes and evaluated retreatment efficacies. Samples of 195 genotype 4-infected patients were collected in the European Resistance Database and investigated for NS3, NS5A and NS5B RASs. Retreatment efficacies in DAA failure patients were analysed retrospectively. After NS5A inhibitor (NS5Ai) failure, subtype 4r was frequent (30%) compared to DAA-naive patients (5%) and the number of NS5A RASs was significantly highe…

medicine.medical_specialtyGenotypeHepatitis C virusMedizinHCV genotype 4HepacivirusViral Nonstructural Proteinsmedicine.disease_causeGastroenterologyAntiviral AgentsVirus03 medical and health scienceschemistry.chemical_compound0302 clinical medicineResistance-associated substitutionsChronic hepatitisMembrane interactionVirologyInternal medicineGenotypeDrug Resistance ViralmedicineHumansIn patient030212 general & internal medicineTreatment FailureNS5ANS5BRetrospective Studiesddc:616Hepatologybusiness.industryHepatitis C virusvirus diseasesHepatitis C Chronicdigestive system diseasesInfectious DiseaseschemistryRetreatmentDAA failure030211 gastroenterology & hepatologybusiness
researchProduct